Harness the Power of Personalized Medicine: The TD2 Solution
TD2 is a biopharma service provider uniquely positioned to meet your development challenges. TD2 integrates world-class clinical and regulatory expertise with "-omic" science and provides unique drug development services aimed at minimizing the risk for clients in the Oncology drug development industry. Our platform, referred to as "De-Risk", is a comprehensive, multi-faceted solution intended to shorten development cycles for anti-cancer agents and improve their success rates.

TGen intern receives another distinguished award for cancer research

TGen researchers find genetic markers to help fight diabetes

‘RainDance’ ships new sequencing solution to TGen

Mexico’s chief genomics official addresses 2009 TGen retreat

$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research from Stand Up to Cancer